Strategic Acquisition: Sun Pharma to Bolster Cancer Treatment Lineup In a $355 million deal, Sun Pharma will acquire Checkpoint Therapeutics, adding the FDA-approved UNLOXCYT to its lineup. The drug addresses advanced skin cancer, and the acquisition aligns with Sun Pharma's global expansion strategy. The transaction awaits regulatory and shareholder approvals, with completion expected by mid-2025.56